Compass Pathways CEO Kabir Nath stated on October 14, 2026, that the company plans to complete its rolling FDA submission for COMP360 synthetic psilocybin treatment in the fourth quarter of 2026.

Overview Debates Related claims Topics Sources

Former NIMH Director Steven Hyman warned at the STAT Summit that psychiatry lacks objective biomarkers to determine which patients will benefit from psychedelic treatments.

The Treatment-Resistant Depression Awareness Day campaign is supported by the National Alliance on Mental Illness, Mental Health America, and the Depression and Bipolar Support Alliance.

Compass Pathways expects COMP360 to be subject to an FDA risk evaluation and mitigation strategy (REMS) upon approval and is investing in provider training for drug administration.

Compass Pathways CEO Kabir Nath stated at the STAT Summit that the company will go slow before it goes fast ahead of the COMP360 FDA submission to avoid early negative patient or provider experiences.

In Compass Pathways Phase 3 trials, roughly 40% of treatment-resistant depression patients experienced a clinically meaningful response after receiving two doses of COMP360 three weeks apart.

Compass Pathways announced the establishment of the first Treatment-Resistant Depression Awareness Day in the U.S. on October 14, 2026.

Former NIMH Director Steven Hyman noted that functional unblinding remains a clinical trial challenge because patients recognize the subjective effects of psychedelic drugs, citing FDA's 2024 rejection of Lykos Therapeutics' MDMA therapy.

Compass Pathways CEO Kabir Nath stated that COMP360 clinical trial session recordings revealed patients spent approximately 80% of session time in silence after the company deliberately separated psychotherapy from trial protocols.

Compass Pathways is engaging commercial insurers and CMS regarding reimbursement mechanisms for clinical monitoring required during COMP360 psilocybin treatment sessions.

COMP360 psilocybin treatment holds Breakthrough Therapy designation from the U.S. FDA and Innovative Licensing and Access Pathway designation in the UK for treatment-resistant depression.

Former NIMH Director Steven Hyman questioned whether subjective psychedelic experiences are necessary for antidepressant efficacy, noting that non-hallucinogenic compounds could allow at-home prescriptions if proven effective.

The Trump administration initiative to advance government-funded ibogaine research follows calls from veterans and experts for strict safety standards on psychedelic treatments.

President Donald Trump signed an executive order in April 2026 dedicating $50 million in federal funding toward research into the psychedelic drug ibogaine.

The Department of Health and Human Services is funding early-stage clinical trials of ibogaine to treat opioid addiction and post-traumatic stress disorder through ARPA-H and NIDA.

The U.S. Food and Drug Administration has opened a public docket seeking feedback by November 20, 2026 on trial design, dose selection, patient eligibility, safety monitoring, and oversight for clinical trials of ibogaine.

Multidisciplinary Association for Psychedelic Studies co-executive director Betty Aldworth stated that solving cardiac safety challenges is the central requirement before ibogaine can responsibly reach patients.

Federal funding for ibogaine clinical trials is justified by its therapeutic potential

The Department of Health and Human Services is prioritizing adults with post-traumatic stress disorder as one of two initial populations for federally supported ibogaine research.

The Department of Health and Human Services is funding early-stage clinical trials of ibogaine through the Advanced Research Projects Agency for Health to examine safety and efficacy in treating post-traumatic stress disorder alongside opioid addiction.

The National Institute on Drug Abuse is funding research on ibogaine for the potential treatment of opioid use disorder in adults.